Y EA R 2001
ANTI INF., 24%
OTHERS DIABETES RESP. CNS NSA IDS NUTRA . GI A NTI INF. CV S
ANTI INF., 16%
YEAR 2010 estimated
ANTI INF. CVS
Source:ORG MARG Retail Audit 2002
Figure 2 presents market share of top therapeutic segment in the year 2001 with projection made for year 2010.However product choice will depend largely on the internal capabilities of the companies. Here it is very much evident from this projection that lots of opportunities lies with chronic therapy segment however growth is initially slow but it may generate good revenue in long run.